Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating whether screening the brain with an MRI (Magnetic Resonance Imaging) scan can help find any hidden brain problems in patients who have been recently diagnosed with stage IV non-small cell lung cancer (NSCLC) that has spread to other parts of the body. The study specifically looks at patients who are generally healthy enough to receive treatment but do not currently show any symptoms of brain disease, such as headaches or changes in vision.

To be eligible for this trial, participants must have a confirmed diagnosis of stage IV metastatic NSCLC, which means the cancer has spread beyond the lungs and cannot be cured. They should also be well enough to tolerate systemic treatment, which is a type of therapy that works throughout the body. However, those who have already received treatment for their cancer, have certain genetic mutations that allow for targeted therapies, or cannot safely undergo an MRI will not be eligible. If you join the study, you will undergo a brain MRI, and the results may help doctors understand how to better manage your cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
• • Fit for systemic treatment (PS 0-2) according to standard of care.
• • No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.
• Exclusion Criteria:
• • Prior/concomitant therapy for stage IV disease.
• • Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
• • Contraindications for MRI scan with contrast as per standard of care protocol of the institution.